The most advanced clinical-stage product candidate in our partner pipeline is Twirla (ethinyl estradiol and levonorgestrel transdermal system), which is being developed by our partner Agile Therapeutics (Agile). Twirla is a combination hormonal contraceptive patch designed to deliver two hormones, ethinyl estradiol and levonorgestrel, at levels comparable to low dose oral contraceptives, through the skin in an easy to use format over seven days. Agile released topline data for its Phase 3 clinical trial of Twirla in January 2017. Based on these data and additional information relating to the manufacture of Twirla, Agile plans to resubmit its NDA in the first half of 2017.
Corium has the exclusive right to manufacture Twirla and we have worked with Agile to prepare facilities and equipment at our Grand Rapids manufacturing site for commercial production of Twirla.
Assuming Twirla is successfully approved and launched commercially, we expect this product will generate a substantial increase in our current product revenues.